A PHASE 1/2, MULTI-CENTER, DOSE-ESCALATING STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS, AND EFFICACY OF QUIZARTINIB ADMINISTERED IN COMBINATION WITH RE-INDUCTION CHEMOTHERAPY, AND AS A SINGLE-AGENT CONTINUATION THERAPY, IN PEDIATRIC RELAPSED/REFRACTORY AML SUBJECTS AGED 1 MONTH TO < 18 YEARS (AND YOUNG ADULTS AGED UP TO 21 YEARS) WITH FLT3-ITD MUTATIONS

Primary Objective

This study plans to learn more about an investigational drug, called quizartinib, that may help to treat AML. An investigational drug is a medication that is still being studied and has not yet been approved for use in your country by the United States Food and Drug Administration (FDA). The FDA allows quizartinib to be used in research. Quizartinib was designed to work against cancer cells that have a FLT3-ITD mutation (a change in one of the genes).

Is This Study For You?

Let's Get Started!

Details
Age
Child to Adult
Locations

Childrens Hospital Colorado

Principal Investigator
Photograph of Margaret Macy

Margaret Macy

Study ID

Protocol Number: 19-2157

More information available at ClinicalTrials.gov: NCT03793478

Categories

Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers